Total Payments
$22,380
2020 Payments
$27.24
Companies
3
Transactions
8
Medicare Patients
83
Medicare Billing
$3,073
Payment Breakdown by Category
Research$22,353 (99.9%)
Education$27.24 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,353 | 7 | 99.9% |
| Education | $27.24 | 1 | 0.1% |
Payments by Type
Research
$22,353
7 transactions
General
$27.24
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Circassia Pharmaceuticals Inc | $19,853 | 6 | $0 (2017) |
| Lupin Inc. | $2,500 | 1 | $0 (2018) |
| AIMMUNE THERAPEUTICS, INC. | $27.24 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2020 | $27.24 | 1 | AIMMUNE THERAPEUTICS, INC. ($27.24) |
| 2018 | $2,500 | 1 | Lupin Inc. ($2,500) |
| 2017 | $19,853 | 6 | Circassia Pharmaceuticals Inc ($19,853) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/19/2020 | AIMMUNE THERAPEUTICS, INC. | PALFORZIA (Biological) | Education | In-kind items and services | $27.24 | General |
| Category: ALLERGY | ||||||
| 04/30/2018 | Lupin Inc. | ADVAIR (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 07/07/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $2,161.48 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 06/02/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $13,476.70 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 05/16/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $893.70 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
| 03/23/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,084.00 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 03/23/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $653.00 | Research |
| Study: A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | ||||||
| 02/10/2017 | Circassia Pharmaceuticals Inc | — | — | Cash or cash equivalent | $1,584.00 | Research |
| Study: An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis | Circassia Pharmaceuticals Inc | $15,214 | 3 |
| An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment | Circassia Pharmaceuticals Inc | $4,639 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF TWICE DAILY ADMINISTRATION OF FLUTICASONE PROPIONATE 100 MCG AND SALMETEROL XINAFOATE 50 MCG DRY POWDER INHALER COMPARED TO ADMINISTRATION WITH ADVAIR DISKUS 10050 MCG TWICE DAILY AND PLACEBO IN PATIENTS 12 YEARS OF AGE AND OLDER WITH REVERSIBLE PERSISTENT ASTHMA INCLUDING A 3-WEEK OPEN-LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $2,500 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 12 | 15 | $570.00 | $137.25 |
| 2021 | 2 | 30 | 33 | $3,267 | $1,621 |
| 2020 | 3 | 41 | 50 | $3,701 | $1,315 |
Total Patients
83
Total Services
98
Medicare Billing
$3,073
Procedure Codes
6
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 12 | 15 | $570.00 | $137.25 | 24.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 21 | $2,226 | $1,383 | 62.1% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2021 | 12 | 12 | $1,041 | $237.80 | 22.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 18 | 20 | $2,120 | $953.02 | 45.0% |
| 94010 | Measurement and graphic recording of total and timed exhaled air capacity | Office | 2020 | 11 | 11 | $954.25 | $260.12 | 27.3% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2020 | 12 | 19 | $627.00 | $102.13 | 16.3% |
About Dr. Edward Kent, MD
Dr. Edward Kent, MD is a Allergy & Immunology healthcare provider based in South Burlington, Vermont. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1124023577.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Edward Kent, MD has received a total of $22,380 in payments from pharmaceutical and medical device companies, with $27.24 received in 2020. These payments were reported across 8 transactions from 3 companies. The most common payment nature is "" ($22,353).
As a Medicare-enrolled provider, Kent has provided services to 83 Medicare beneficiaries, totaling 98 services with total Medicare billing of $3,073. Data is available for 3 years (2020–2023), covering 6 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy & Immunology
- Location South Burlington, VT
- Active Since 06/14/2005
- Last Updated 07/09/2007
- Taxonomy Code 207K00000X
- Entity Type Individual
- NPI Number 1124023577
Products in Payments
- ADVAIR (Drug) $2,500
- PALFORZIA (Biological) $27.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.